Abstract:Kamila Justyna Bienkowska, Christopher Jon Hanley School of Cancer Sciences, University of Southampton, Southampton, UK Comment on: Hu J, Zhang L, Xia H, et al . Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med 2023;15:14. Keywords: Non-small cell lung cancer (NSCLC); immunotherapy; single-cell RNA sequencing Submitted Jun 30, 2023. Accepted for publication Aug 01, 2023. Published online Aug 08, 2023. doi: 10.21037/tlcr-23-428 Lung cancer is the leading cause of cancer-related deaths worldwide. In recent years, immune checkpoint blockade (ICB) has been widely used for the treatment of non-small cell lung cancer (NSCLC)—the predominant lung cancer subtype. However, ICB response rates remain limited. For example, analysis of multiple NSCLC trials using nivolumab showed this treatment increased 4-year overall survival rates from 5% to 14% but only achieved complete or partial responses in 16% of cases (1). Further understanding of how the tumour microenvironment changes in response to ICB, specifically what cell populations and/or molecular mechanisms drive response and resistance, is required to improve ICB efficacy through predictive biomarkers and novel combination therapies. In a recent study published in Genome Medicine (2), Hu et al. used a multi-modal approach to investigate changes in the NSCLC multicellular ecosystem that underpin response to chemotherapy and ICB combination treatment in NSCLC. This study utilised bulk tissue and single cell (sc)RNA-sequencing, immunostaining and in silico modelling to investigate mechanisms associated with major pathological response (MPR). ScRNA-sequencing was performed on 3 treatment naive (TN) tumour biopsies; and 12 surgically resected tumour specimens following neo-adjuvant chemotherapy and ICB; a subset of these samples was also analysed by multi-marker immunostaining. Pathological response varied within the 12 post-treatment samples, with MPR achieved in 4 cases (leaving 8 exhibiting non-MPR). An independent TN cohort (n=21) was also examined with bulk RNA-sequencing, enabling the evaluation of molecular signatures' potential as predictive biomarkers. Despite this relatively small sample size, the study revealed multiple cell subpopulations and molecular signatures that varied between pathological response groups, providing valuable insight into key drivers of response to combined chemotherapy and ICB in NSCLC ( Figure 1 ). Furthermore, many of these findings may also have implications for other solid cancers, as key findings were validated in cohorts of melanoma patients treated with ICBs. The principle aim of ICB is to overcome CD8 + T-cell suppression and initiate cytotoxic clearance of tumour cells (3). In NSCLC, ICB treatments most commonly target the interaction between the PD-1 receptor and ligands PD-L1/L2. Nivolumab (anti-PD-1) was the first immune checkpoint inhibitor approved for use in lung cancer, soon followed by pembrolizumab, cemiplimab, sintilimab, toripalimab and camrelizumab (the latter three were used in Hu et al. 's study). Anti-PD-L1 drugs atezolizumab and durvalumab have also been approved for use in NSCLC. Depending on national regulatory approvals, these drugs are used in a variety of clinical settings: including first-line neo-adjuvant therapy in combination with chemotherapy (as investigated in Hu et al. 's study); adjuvant treatment following surgery and chemotherapy; second-line monotherapy and as consolidation therapy in patients unable to undergo surgery (4-7). Given that the efficacy of PD-1 blockade is predicated on establishing an adaptive immune response against the tumour, it is not surprising that Hu et al. found significant enrichment of T-cells and B-cells within the stromal compartment of MPR samples compared to both TN and non-MPR samples. However, closer examination of the phenotypic heterogeneity within these immune microenvironments, enabled by scRNA-seq analysis, demonstrated that specific immune cell subpopulations were variably abundant between these sample groups and also highlighted novel epithelial phenotypes associated with treatment response. Ten clusters of epithelial cells were identified in Hu et al. 's scRNA-seq analysis. Non-malignant (diploid) clusters (representing AT1, AT2, club, basal and ciliated cells), were generally enriched in the MPR group. This was suggested to represent alveolar regeneration following ablation of the malignant epithelium in patients who positively responded to therapy. Notably, CX3CL1 and genes associated with antigen presentation via major histocompatibility complex (MHC)-Class II were found to be up-regulated in the epithelial compartment of MPR samples. MHC-Class II machinery is typically expressed by profess -Abstract Truncated-

Mise en évidence d'une reprogrammation métabolique des neutrophiles circulants chez les patients atteints de cancer bronchique pulmonaire non à petites cellules métastatiques

The Prognostic Impact of Neutrophil to Lymphocyte Ratio in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors.

Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?

Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial

Incidence, caractéristiques et survie des patients présentant une pneumocystose en oncologie solide

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

Abstract C020: Neutrophil-mediated stromal-tumor IL-6/STAT-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study

Abstract PR-08: Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis

Cancers bronchiques non à petites cellules chez les adultes de moins de 40 ans : caractéristiques épidémiologiques, cliniques, histologiques et biologiques

Metabolic features of cancer cells impact immunosurveillance

Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy

Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis

Abstract 3702: Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy

Étude de la physiopathologie de la dysfonction chronique du greffon pulmonaire par analyse transcriptomique sur cellule unique d'explants pulmonaires

Single‐cell and spatial transcriptomics reveal POSTN+ cancer‐associated fibroblasts correlated with immune suppression and tumour progression in non‐small cell lung cancer

Abstract 5181: The role of Neuropilin-1 signaling in CD4 conventional T cell immune function in non-small cell lung cancer

Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance

CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors

Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.

Improved understanding of NSCLC immunotherapy response mechanisms from single-cell analysis